In the present study, we assessed the ability of the TSAT/hepcidin ratio to distinguish biallelic and monoallelic affected IRIDA patients from patients with IDA due to other causes, such as hypermenorrhea, gastrointestinal hemorrhage, and malabsorption, who had no signs of moderate-to-severe inflammation and who have not received recent iron therapy to preclude significant modulation of the hepcidin regulatory pathway that could affect the ratio between TSAT and hepcidin [8,15,16,17,18,19,20]. The gene discussed is HAMP; the disease is Gastrointestinal hemorrhage.